Biosynexus, a biotechnology-pharmaceutical company that is commercializing a portfolio of products for the prevention and treatment of infectious diseases, has been acquired for an unspecified sum by the QVT Fund. Biosynexus also announced that Dr. Irwin Scher has been appointed CEO. "It is very exciting to be joining a company with such tremendous potential, and to be coming on board with QVT Fund LP as our parent company," said Dr. Scher. "This will provide us with the additional capital for completing our clinical trials and for further investment in, and expansion of, our current pipeline."
- read this press release for more